High DND1 Level Indicates a Poor Prognostic Factor in Prostate Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Dead end 1 (DND1) is implicated in oncogenesis and cancer progression by regulating mRNA via miRNA interactions.
• Its specific role in prostate cancer (PCa) pathogenesis remained largely undetermined prior to this study.

Purpose of the Study:

• To investigate the correlation between DND1 expression levels and clinical characteristics in prostate cancer patients.
• To evaluate DND1 as a potential prognostic biomarker for PCa.

Main Methods:

• Immunohistochemistry was employed to assess DND1 expression in 83 prostate cancer tumor specimens versus paired adjacent non-cancerous tissues.
• The Cancer Genome Atlas (TCGA) database was utilized for external validation of DND1 expression findings.
• Statistical analyses were performed to correlate DND1 expression with clinical parameters and patient prognosis.

Main Results:

• DND1 exhibited significantly higher expression levels in prostate cancer tissues compared to paracancerous tissues.
• Overexpression of DND1 protein was strongly associated with advanced clinical stage, higher ISUP grading, seminal vesicle invasion, and elevated PSA density.
• Elevated DND1 expression correlated with a poorer clinical prognosis in prostate cancer patients.

Conclusions:

• High DND1 expression is linked to prostate cancer progression and adverse clinical outcomes.
• DND1 demonstrates potential as a valuable prognostic biomarker for prostate cancer.
• Further research into DND1's role could inform therapeutic strategies for PCa.